Chokri Ben Lamine: Platelet Subpopulations and Targeted Therapies Across Evidence Levels
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Study Stage / Evidence Level – Platelet Subpopulation – Targeted Therapies
Reversible P2Y12 inhibitors (ticagrelor / cangrelor)
- Stage: Phase III (established clinical practice)
- PLATO trial – robust RCT evidence – guideline standard in ACS
- Highest level evidence (Class I recommendation in cardiology guidelines)
GPVI inhibitors (glenzocimab, revacept)
- Stage: Phase II clinical trials
- PCI studies – good safety (decreased bleeding)
- Efficacy signal modest – no reduction in MI yet
- Promising but NOT standard of care
PI3K inhibition (LY294002)
- Stage: Preclinical / experimental
- Mechanistic targeting only
- No clinical application currently
COX-2 targeting / aspirin adjustment
- Stage: Mixed clinical data (small trials / observational)
- No consistent benefit – not guideline recommended
- Conceptual explanation for aspirin resistance
Platelet–immune axis (VEGF / PDGF / αIIbβ3 in cancer)
- Stage: Early clinical / exploratory (e.g., APOLLO study)
- Signal for improved outcomes with ICI combinations
- Hypothesis-generating – not standard oncology practice
S100A8/A9 inhibitors (ABR-215757)
- Stage: Preclinical models
- Demonstrated decreased RP-driven thrombosis
- No human outcome trials yet
SGLT2 inhibitors (indirect platelet modulation)
- Stage: Phase III cardiovascular outcome trials (indirect evidence)
- Proven decreased CV events – platelet benefit inferred
- Not platelet-specific indication but clinically relevant
Summary hierarchy (very high yield)
Phase III / Standard: Ticagrelor / Cangrelor
Phase II / Emerging: GPVI inhibitors
Preclinical / Experimental:
- PI3K inhibitors
- S100A8/A9 inhibitors
Hypothesis / Mixed evidence:
- COX-2 targeting
- Platelet–immune modulation
Clinical pearl
- Only P2Y12 reversible inhibitors currently translate platelet subpopulation biology into routine practice.
- Everything else is precision medicine pipeline (future hematology/cardiology integration).”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients